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Abstract
Background: The two 52-week INPULSIS trials investigated nintedanib versus placebo in patients with IPF, FVC
≥50% predicted and DLco 30–79% predicted. The 24-week INSTAGE trial investigated nintedanib plus sildenafil
versus nintedanib alone in patients with IPF and DLco ≤35% predicted. We used data from INPULSIS and INSTAGE
to compare the effects of nintedanib in patients with IPF with less versus more severe impairment in gas exchange
at baseline.
Methods: Analyses were conducted in patients treated with nintedanib alone in the INPULSIS and INSTAGE trials
and in patients treated with placebo in the INPULSIS trials. Outcomes included the rate of decline in FVC over 24
weeks, the proportions of patients who had a confirmed or suspected idiopathic acute exacerbation over 24 weeks,
deaths over 24 weeks, and adverse events. Analyses were descriptive.
Results: In total, 638 and 136 patients received nintedanib alone in the INPULSIS and INSTAGE trials, respectively,
and 423 patients received placebo in the INPULSIS trials. Rates of FVC decline were − 52.3 and − 66.7 mL/24 weeks
in patients treated with nintedanib alone in INPULSIS and INSTAGE, respectively, and − 102.8 mL/24 weeks in
patients treated with placebo in INPULSIS. Confirmed or suspected idiopathic acute exacerbations were reported in
0.6 and 3.7% of patients treated with nintedanib alone in INPULSIS and INSTAGE, respectively, and 2.1% of patients
treated with placebo in INPULSIS. Deaths occurred in 2.0, 11.0 and 1.9% of patients in these groups, respectively.
Diarrhoea adverse events were reported in 52.5 and 48.5% of patients treated with nintedanib alone in INPULSIS
and INSTAGE, respectively, and 16.1% of patients treated with placebo in INPULSIS.
Conclusions: Based on data from the INSTAGE and INPULSIS trials, nintedanib had a similar effect on FVC decline
over 24 weeks, and a similar safety and tolerability profile, in patients with IPF and more versus less severe
impairment in gas exchange. These data support the use of nintedanib in patients with IPF who have advanced
disease.
Trial registration: INPULSIS (NCT01335464 and NCT01335477); INSTAGE (NCT02802345).
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Background
Idiopathic pulmonary fibrosis (IPF) is a progressive
fibrosing interstitial lung disease associated with decline
in lung function, worsening dyspnoea and quality of life,
and considerable mortality [1, 2]. While IPF progresses
in all patients, the pattern of disease progression is vari-
able and remains a challenge to predict [3, 4]. A better
evidence base for the treatment of severe IPF remains an
unmet need [5].
Nintedanib is a treatment for IPF. In the two 52-week
INPULSIS trials, nintedanib reduced the annual rate of
decline in forced vital capacity (FVC) (mL/year) by ap-
proximately 50% compared with placebo in patients with
IPF and mild or moderate impairment in lung function
at baseline, with an adverse event profile predominantly
characterised by gastrointestinal events [6]. In the 24-
week INSTAGE trial, nintedanib plus sildenafil was asso-
ciated with a numerical but not statistically significant
benefit on change in St. George’s Respiratory Question-
naire (SGRQ) total score compared with nintedanib
alone in patients with IPF and severely impaired gas
exchange (diffusing capacity of the lungs for carbon
monoxide [DLco] ≤35% predicted) at baseline [7].
Few data are available on the efficacy and safety of
antifibrotic therapies in patients with advanced IPF. We
used data from the INPULSIS and INSTAGE trials to
compare the effects of nintedanib in patients with IPF
and less versus more severe impairment in gas exchange
at baseline.
Methods
The designs of the INPULSIS and INSTAGE trials have
been published [6, 7]. Briefly, in the INPULSIS trials,
patients with FVC ≥50% predicted and DLco 30–79%
predicted were randomised 3:2 to receive nintedanib
150 mg twice daily (bid) or placebo for 52 weeks, with a
follow-up visit 4 weeks later. The primary endpoint was
the annual rate of decline in FVC (mL/year) [6]. In the
INSTAGE trial, patients with IPF and DLco ≤35% pre-
dicted were randomised 1:1 to receive nintedanib 150
mg bid plus sildenafil or nintedanib 150 mg bid plus pla-
cebo for 24 weeks, with a follow-up visit 4 weeks later.
The primary endpoint was the change from baseline in
SGRQ total score at week 12 [7]. In all these trials, FVC
data were converted to per cent predicted values using
the European Community for Steel and Coal equations
[8]. In the INPULSIS trials, DLco data were converted to
% predicted using the equation published by Crapo [9].
In INSTAGE, sites used different equations to calculate
per cent predicted values for DLco.
Spirometry was performed at baseline and weeks 2, 4,
6, 12 and 24 in the INPULSIS trials [6], and at baseline
and weeks 4, 8, 12, 18 and 24 in the INSTAGE trial [7].
The SGRQ was completed by patients at baseline and
weeks 6, 12 and 24 in the INPULSIS trials [6], and at
baseline and weeks 4, 12 and 24 in the INSTAGE trial
[7]. The SGRQ assesses health-related quality of life
(HRQL); there are 50 items and the total score ranges
from 0 to 100, with higher scores indicating worse
HRQL [10]. In the INPULSIS trials, acute exacerbations
were defined as events that met the following criteria:
unexplained worsening or development of dyspnoea
within 30 days; new diffuse pulmonary infiltrates on
chest X-ray and/or HRCT parenchymal abnormalities
with no pneumothorax or pleural effusion (new ground-
glass opacities) since last visit; causes of the acute wors-
ening, including infection, left heart failure, pulmonary
embolism, or any identifiable cause of acute lung injury
excluded as per routine clinical practice and microbio-
logical studies [6]. In the INSTAGE trial, an acute
exacerbation was defined as an event that met the
following criteria: acute worsening or development of
dyspnoea, typically of less than 1-month duration; com-
puted tomography with new bilateral ground-glass opa-
city and/or consolidation superimposed on background
pattern consistent with usual interstitial pneumonia
pattern; deterioration not fully explained by cardiac fail-
ure or fluid overload; extra-parenchymal causes (e.g.
pneumothorax, pleural effusion, pulmonary embolism)
were excluded [7]. In both the INPULSIS and INSTAGE
trials, acute exacerbations were adjudicated by a blinded
committee as confirmed, suspected, or not acute exacer-
bations [6.7]. In the INPULSIS trials, events deemed to
be acute exacerbations but did not meet all protocol-
specified criteria for an acute exacerbation were classified
as suspected acute exacerbations [6]. In the INSTAGE
trial, events deemed to be acute exacerbations but had
missing CT data were classified as suspected acute exacer-
bations [7]. In the INSTAGE trial, confirmed/suspected
acute exacerbations were further adjudicated as idiopathic
or triggered based on the criteria described in the 2016
international working group report [7, 11]. All confirmed/
suspected acute exacerbations in the INPULSIS trials were
idiopathic [6].
In the current analyses, we investigated changes from
baseline in FVC (mL) and SGRQ total score at weeks 12
and 24; the rate of decline in FVC (mL) over 24 weeks;
and the proportions of patients who had an absolute
decline in FVC ≥5% predicted or died, had an adjudi-
cated confirmed or suspected idiopathic acute exacerba-
tion, or who died from any cause over 24 weeks in
patients who received nintedanib alone in the INPULSIS
and INSTAGE trials and in patients who received pla-
cebo in the INPULSIS trials. For each endpoint, the
same statistical approach was used as in the primary
analyses [6, 7]. Changes from baseline in FVC and SGRQ
total score at weeks 12 and 24 were analysed using
mixed effects models for repeated measures. The rate of
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decline in FVC over 24 weeks was analysed using a ran-
dom coefficient regression model. These models allowed
for missing data, assuming they were missing at random.
Adverse events were reported by the investigators irre-
spective of causality and coded based on preferred terms
in the Medical Dictionary for Regulatory Activities
(MedDRA) (version 20.1 in INPULSIS and version 21.0
in INSTAGE) [6, 7]. In the INPULSIS trials, adverse
events with onset between the first dose of trial drug
and day 195 (or between the first dose and 28 days after
the last dose for patients who discontinued trial drug be-
fore week 24) were included [6]. In the INSTAGE trial,
adverse events with onset between the first dose and up
to 28 days after the last dose of trial drug were included.
Safety analyses were descriptive [7]. All efficacy and
safety analyses were based on patients who received ≥1
dose of trial drug.
Results
Patients
Overall, 638 and 136 patients received nintedanib alone
in the INPULSIS and INSTAGE trials, respectively; 423
patients received placebo in the INPULSIS trials. In
accordance with the eligibility criteria, mean DLco %
predicted at baseline was higher in INPULSIS than in
INSTAGE (47.2% versus 25.6% predicted). In addition,
patients in the INPULSIS trials were younger and had
higher FVC % predicted and lower SGRQ total score
(indicating better health-related quality of life) than
patients in the INSTAGE trial (Table 1).
Lung function
Mean (SE) absolute changes from baseline in FVC at week
12 were − 25.4 (9.8) and − 25.5 (15.7) mL in patients treated
with nintedanib alone in INPULSIS and INSTAGE,
respectively, and − 78.8 (11.3) mL in patients treated with
placebo in INPULSIS (Fig. 1). Mean (SE) absolute changes
from baseline in FVC at week 24 were − 52.8 (9.8) and −
58.2 (19.6) mL in patients treated with nintedanib alone
in INPULSIS and INSTAGE, respectively, and − 106.4
(11.4) mL in patients treated with placebo in INPULSIS
(Fig. 2). The rate of decline in FVC (mL) over 24 weeks
was consistent with the changes from baseline in FVC
(mL) at week 24 (Fig. 3).
Over 24 weeks, an absolute decline in FVC ≥5% pre-
dicted or death occurred in 190 (29.8%) and 69 (50.7%)
patients treated with nintedanib alone in INPULSIS and
INSTAGE, respectively, and 174 (41.1%) patients treated
with placebo in INPULSIS.
Health-related quality of life
Mean (SE) changes from baseline in SGRQ total score at
week 12 were 0.38 (0.51) and − 0.77 (1.0) in patients treated
with nintedanib alone in INPULSIS and INSTAGE,
respectively, and 0.10 (0.61) in patients treated with pla-
cebo in INPULSIS. Mean (SE) changes in SGRQ total score
at week 24 were 1.05 (0.53) and 2.42 (1.16) in patients
treated with nintedanib alone in INPULSIS and INSTAGE,
respectively, and 1.78 (0.68) in patients treated with pla-
cebo in INPULSIS.
Acute exacerbations and mortality
Confirmed or suspected idiopathic acute exacerbations
occurred in 4 (0.6%) and 5 (3.7%) patients treated with
nintedanib alone in INPULSIS and INSTAGE, respect-
ively, and 9 (2.1%) patients treated with placebo in
INPULSIS. Deaths occurred in 13 (2.0%) and 15 (11.0%)
patients treated with nintedanib alone in INPULSIS and
Table 1 Baseline characteristics of patients in the INPULSIS and INSTAGE trials
INPULSIS INSTAGE
Nintedanib (n = 638) Placebo (n = 423) Nintedanib (n = 136)
Age, years, mean (SD) 66.6 (8.1) 67.0 (7.9) 70.0 (7.9)
Male, n (%) 507 (79.5) 334 (79.0) 106 (77.9)
Body mass index, kg/m2 28.1 (4.6) 27.6 (4.6) 26.5 (4.7)
Race, n (%)
White 360 (56.4) 248 (58.6) 95 (69.9)
Asian 194 (30.4) 128 (30.3) 39 (28.7)
Othera 84 (13.2) 47 (11.1) 2 (1.5)
Time since diagnosis of IPF, years, mean (SD) 1.7 (1.4) 1.6 (1.3) 2.1 (1.8)
FVC, % predicted, mean (SD) 79.7 (17.6) 79.3 (18.2) 66.1 (18.7)
FEV1/FVC ratio, %, mean (SD) 81.7 (5.8) 81.7 (6.0) 83.8 (7.6)
DLco, % predicted, mean (SD)b 47.4 (13.5) 47.0 (13.4) 25.6 (7.0)
SGRQ total score, mean (SD)c 39.5 (19.2) 39.6 (18.5) 54.0 (17.9)
aIncludes patients with missing data. In INPULSIS, it was not permitted to collect data on race in France. bCorrected for haemoglobin; INPULSIS: n = 422 in placebo
group; INSTAGE: n = 135 in nintedanib group. cINPULSIS: n = 624 in nintedanib group and n = 419 in placebo group; INSTAGE: n = 133 in nintedanib group
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INSTAGE, respectively, and in 8 (1.9%) patients treated
with placebo in INPULSIS.
Safety and tolerability
An overview of adverse events reported in the INPULSIS
and INSTAGE trials is provided in Table 2. Adverse
events leading to treatment discontinuation were reported
in 90 (14.1%) and 23 (16.9%) patients treated with ninteda-
nib alone in INPULSIS and INSTAGE, respectively, and
32 (7.6%) patients who received placebo in INPULSIS.
Diarrhoea was reported in 335 (52.5%) and 66 (48.5%) pa-
tients treated with nintedanib alone in INPULSIS and
INSTAGE, respectively, and 68 (16.1%) patients treated
with placebo in INPULSIS, and led to premature treat-
ment discontinuation in 24 (3.8%) and 3 (2.2%) patients
treated with nintedanib in INPULSIS and INSTAGE,
respectively, and in no patients who received placebo. Ser-
ious adverse events were reported in 107 (16.8%) and 44
(32.4%) patients treated with nintedanib alone in INPUL-
SIS and INSTAGE, respectively, and 72 (17.0%) patients
treated with placebo in INPULSIS (Table 3).
Discussion
Patients with severe lung function impairment have been
excluded from most clinical trials of treatments for IPF.
As a result, far fewer data are available on the efficacy
and safety of therapies in patients with advanced disease
than milder disease. Here we have shown, based on data
from the INPULSIS and INSTAGE trials, that ninteda-
nib appears to have a similar effect on FVC decline over
24 weeks in patients with IPF irrespective of their sever-
ity of gas exchange impairment at baseline. Previous
analyses of data from the INPULSIS trials have shown
that nintedanib has a consistent effect in reducing FVC
decline in subgroups of patients with baseline DLco
≤40% versus > 40% predicted [12] and FVC ≤70% versus
Fig. 1 Absolute changes from baseline in FVC (mL) at week 12 in the INPULSIS and INSTAGE trials
Fig. 2 Absolute changes from baseline in FVC (mL) at week 24 in the INPULSIS and INSTAGE trials
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> 70% predicted [13]. Data from an interim analysis of
INPULSIS-ON, the open-label extension of the INPUL-
SIS trials, suggested that, albeit with the limitations of
an open-label design and small sample size, the efficacy
and safety of nintedanib were similar in patients with
FVC ≤50% predicted at entry into INPULSIS-ON as in
patients with less severe disease [14]. A growing body of
observational evidence collected in clinical practice
suggests that nintedanib is efficacious in reducing
disease progression in patients with severe lung function
impairment [15–19]. Taken together, these findings sup-
port the use of nintedanib in patients with IPF who have
advanced disease.
Physicians may be reluctant to treat patients with ad-
vanced IPF due to uncertainty about the efficacy and/or
safety of antifibrotic therapies in these patients, or to
Fig. 3 Rate of decline in FVC (mL/24 weeks) in the INPULSIS and INSTAGE trials
Table 2 Adverse events in the INPULSIS and INSTAGE trials
INPULSIS INSTAGE
Nintedanib (n = 638) Placebo (n = 423) Nintedanib (n = 136)
Adverse events 580 (90.9) 345 (81.6) 127 (93.4)
Most frequent adverse eventsa
Diarrhoea 335 (52.5) 68 (16.1) 66 (48.5)
Nausea 145 (22.7) 25 (5.9) 14 (10.3)
Decreased appetite 53 (8.3) 16 (3.8) 23 (16.9)
Nasopharyngitis 62 (9.7) 43 (10.2) 8 (5.9)
Cough 61 (9.6) 35 (8.3) 13 (9.6)
Vomiting 61 (9.6) 11 (2.6) 10 (7.4)
Dyspnoea 30 (4.7) 25 (5.9) 13 (9.6)
Progression of IPFb 33 (5.2) 34 (8.0) 12 (8.8)
Weight decreased 41 (6.4) 8 (1.9) 12 (8.8)
Abdominal pain 53 (8.3) 6 (1.4) 9 (6.6)
Adverse events leading to treatment discontinuation 90 (14.1) 32 (7.6) 26 (19.1)
Most frequent adverse events leading to treatment discontinuationc
Diarrhoea 24 (3.8) 0 3 (2.2)
Nausea 12 (1.9) 0 0
Progression of IPFb 7 (1.1) 12 (2.8) 0
Data are n (%) of patients with ≥1 such event. In INPULSIS, events with onset between the first dose of trial drug and day 195 (or between the first dose and 28
days after the last dose for patients who discontinued trial drug before week 24) were included. In INSTAGE, events with onset between the first dose and up to
28 days after the last dose of trial drug were included. aReported in > 8% of patients in any of the groups shown, based on MedDRA preferred terms.
bCorresponds to MedDRA term ‘IPF’, which included disease worsening and acute exacerbations. cReported in > 1.5% of patients in any of the groups shown,
based on MedDRA preferred terms
Richeldi et al. BMC Pulmonary Medicine            (2020) 20:3 Page 5 of 8
concerns over the tolerability of antifibrotic therapies in
patients who are old or have comorbidities [20]. However,
many of the patients with IPF who require care in clinical
practice have advanced impairment in lung function. Data
from 662 patients in the IPF-PRO Registry, a US registry
of patients with IPF that was diagnosed or confirmed at
the enrolling centre in the past 6months, showed that
25% of patients had DLco < 31.3% predicted and 25% had
FVC < 60.1% predicted [21]. Similar degrees of impair-
ment in FVC and DLco have been observed in other con-
temporary registries of patients with IPF [22].
Nintedanib had a similar adverse event profile in pa-
tients with mild or moderate impairment in gas ex-
change in the INPULSIS trials and in patients with more
severe disease in the INSTAGE trial, albeit with a greater
frequency of serious adverse events in patients with
more severe disease, as might be expected in a sicker
population. Previous analyses of safety data from clinical
trials of nintedanib have shown a consistent safety and
tolerability profile across trials and patient subgroups
[13, 14, 23]. Real-world data from clinical practice sug-
gest that the safety and tolerability profile of nintedanib
is similar in patients with IPF who have severe disease as
in patients with milder disease, but that patients with
more severe disease have a higher rate of treatment dis-
continuation [16, 18, 24]. This highlights the importance
of patient education and proactive management of side-
effects in patients prescribed nintedanib for the treat-
ment of IPF [25, 26].
In our analyses, HRQL at baseline, assessed using the
SGRQ total score, was worse in patients in the
INSTAGE trial than in the INPULSIS trials. Previous
studies have also shown that patients with IPF who have
more advanced disease based on % predicted values for
FVC and/or DLco have worse symptoms, worse exercise
capacity, and worse HRQL [27–29]. In both the INPUL-
SIS and INSTAGE trials, changes in SGRQ total score
over 24 weeks were small, consistent with previous stud-
ies showing that small changes in FVC are not associ-
ated with meaningful changes in the patient-reported
outcomes commonly used in patients with IPF [30, 31].
As expected, the risk of idiopathic acute exacerbations
was higher in patients with more advanced disease in the
INSTAGE trial than in patients in the INPULSIS trials. A
wealth of data has demonstrated that low FVC and/or low
DLco are risk factors for acute exacerbations in patients
with IPF [11, 32, 33], possibly because patients with more
advanced disease are more vulnerable to insults such as
infection that may lead to an acute exacerbation [11].
Similarly, the risk of mortality was higher in patients with
more severe impairment in DLco in the INSTAGE trial
than in patients in the INPULSIS trials, consistent with
previous studies identifying low DLco as a risk factor for
mortality in patients with IPF [4, 33, 34].
Our analyses have limitations, including differences
between the INPULSIS and INSTAGE trial populations
beyond impairment in lung function; the lack of a pla-
cebo group in the INSTAGE trial; the short duration of
the study; the use of different equations for calculation
of per cent predicted values for DLco; and the post-hoc
nature of the analyses of data from the INPULSIS trials.
Nonetheless, our data add to the body of evidence on
Table 3 Serious adverse events in the INSTAGE and INPULSIS trials
INPULSIS INSTAGE
Nintedanib (n = 638) Placebo (n = 423) Nintedanib (n = 136)
Serious adverse eventsa 107 (16.8) 72 (17.0) 44 (32.4)
Most frequent serious adverse eventsb
Progression of IPFc 23 (3.6) 21 (5.0) 9 (6.6)
Pneumonia 14 (2.2) 10 (2.4) 8 (5.9)
Pulmonary hypertension 4 (0.6) 7 (1.7) 4 (2.9)
Respiratory failure 0 0 3 (2.2)
Right ventricular failure 0 0 3 (2.2)
Pulmonary embolism 3 (0.5) 2 (0.5) 2 (1.5)
Lower respiratory tract infection 1 (0.2) 2 (0.5) 2 (1.5)
Respiratory tract infection 0 2 (0.5) 2 (1.5)
Dyspnoea 1 (0.2) 2 (0.5) 2 (1.5)
Acute respiratory failure 2 (0.3) 1 (0.2) 2 (1.5)
Data are n (%) of patients with ≥1 such event. In INPULSIS, events with onset between the first dose of trial drug and day 195 (or between the first dose and 28
days after the last dose for patients who discontinued trial drug before week 24) were included. In INSTAGE, events with onset between the first dose and up to
28 days after the last dose of trial drug were included. aEvents that resulted in death, were life-threatening, resulted in hospitalisation or prolonged hospitalisation,
resulted in persistent or clinically significant disability or incapacity, were a congenital anomaly or birth defect, or were deemed serious for any other reason.
bReported in ≥1.5% of patients in any of the groups shown, based on MedDRA preferred terms. cCorresponds to MedDRA term ‘IPF’, which included disease
worsening and acute exacerbations
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the efficacy and safety of nintedanib in patients with IPF
and advanced disease.
Conclusion
Based on data from the INPULSIS and INSTAGE trials,
nintedanib appears to have a similar effect on FVC de-
cline over 24 weeks, and a similar safety and tolerability
profile, in patients with IPF irrespective of their severity
of gas exchange impairment at baseline. These data sup-
port the use of nintedanib in patients with IPF who have
advanced disease.
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